Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free ASTH Stock Alerts

Astrana Health (ASTH) Financials

Astrana Health logo
$37.98 -0.05 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$38.02 +0.05 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Astrana Health

Annual Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.80 11 26 11 14 38 69 45 61 43 22
Consolidated Net Income / (Loss)		 -1.35 10 46 60 18 122 46 46 58 50 24
Net Income / (Loss) Continuing Operations		 -1.35 10 46 60 18 122 46 46 58 50 24
Total Pre-Tax Income 		-1.18 19 50 83 26 178 78 87 90 81 40
Total Operating Income		 -0.69 12 35 88 32 81 98 104 85 89 79
Total Gross Profit		 11 51 83 155 94 148 178 199 215 271 342
Total Revenue		 33 306 356 520 561 687 774 1,144 1,387 2,035 3,182
Operating Revenue		 33 282 356 520 561 687 774 1,144 1,387 2,035 3,182
Total Cost of Revenue		 22 255 273 365 466 539 596 945 1,172 1,763 2,840
Operating Cost of Revenue		 22 255 273 361 468 539 596 945 1,172 1,763 2,840
Total Operating Expenses		 12 39 48 66 62 67 80 95 130 182 263
Selling, General & Admin Expense		 11 21 26 43 41 49 62 78 113 154 217
Depreciation Expense		 0.33 18 19 19 18 18 18 18 18 28 46
Total Other Income / (Expense), net		 -0.49 7.15 15 -5.81 -6.58 98 -20 -18 5.23 -8.53 -39
Interest Expense		 1.33 0.06 0.08 0.56 4.73 9.50 5.39 7.92 16 33 50
Interest & Investment Income		 - 5.25 14 -6.87 -4.88 106 -0.54 7.60 20 19 14
Other Income / (Expense), net		 0.84 1.96 1.05 1.62 3.03 1.08 -14 -17 1.54 5.61 -2.86
Income Tax Expense		 0.16 8.82 3.89 22 8.17 56 32 41 32 31 16
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.45 -1.43 20 49 3.56 84 -23 0.57 -2.87 6.78 1.59
Basic Earnings per Share		 ($0.37) $0.46 $1.01 $0.33 $0.41 $1.03 $1.57 $1.00 $1.30 $0.91 $0.46
Weighted Average Basic Shares Outstanding		 4.89M 24.67M 25.53M 32.89M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M
Diluted Earnings per Share		 ($0.37) $0.41 $0.90 $0.29 $0.39 $1.01 $1.52 $0.99 $1.29 $0.90 $0.46
Weighted Average Diluted Shares Outstanding		 4.89M 27.97M 28.66M 37.91M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M
Weighted Average Basic & Diluted Shares Outstanding		 4.89M 5.21M 6.95M 32.80M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M

Quarterly Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 12 15 19 16 -6.95 6.69 9.42 0.37 6.00 14 20
Consolidated Net Income / (Loss)		 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56 13 18
Net Income / (Loss) Continuing Operations		 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56 13 18
Total Pre-Tax Income 		0.92 24 32 27 -1.90 9.60 17 5.67 7.51 20 27
Total Operating Income		 -3.87 30 30 28 0.72 21 20 19 18 29 34
Total Gross Profit		 39 74 73 73 50 71 78 97 95 106 104
Total Revenue		 353 404 486 479 665 620 655 956 951 965 973
Operating Revenue		 353 404 486 479 665 620 655 956 951 965 973
Total Cost of Revenue		 314 330 413 405 615 549 577 859 855 859 868
Operating Cost of Revenue		 314 330 413 405 615 549 577 859 855 859 868
Total Operating Expenses		 43 44 43 45 50 51 58 78 77 77 70
Selling, General & Admin Expense		 38 39 36 38 42 44 51 62 60 62 54
Depreciation Expense		 4.90 5.10 7.44 7.26 8.13 6.85 6.90 16 16 15 16
Total Other Income / (Expense), net		 4.80 -6.14 1.83 -1.61 -2.62 -11 -3.52 -14 -11 -8.82 -7.11
Interest Expense		 5.42 7.59 8.59 8.86 8.07 7.31 7.38 18 18 16 16
Interest & Investment Income		 7.07 4.63 4.42 5.13 4.79 1.45 2.72 4.54 5.16 5.54 6.46
Other Income / (Expense), net		 3.15 -3.18 6.00 2.11 0.67 -5.12 1.15 -0.36 1.47 1.75 2.43
Income Tax Expense		 1.02 7.14 10 7.83 5.88 3.38 6.61 4.59 0.94 6.58 8.76
Net Income / (Loss) Attributable to Noncontrolling Interest		 -12 2.03 2.70 2.89 -0.83 -0.47 0.79 0.70 0.56 -1.31 -1.29
Basic Earnings per Share		 $0.27 $0.31 $0.40 $0.34 ($0.14) $0.14 $0.19 $0.01 $0.12 $0.30 $0.40
Weighted Average Basic Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M
Diluted Earnings per Share		 $0.26 $0.31 $0.40 $0.33 ($0.14) $0.14 $0.19 $0.01 $0.12 $0.29 $0.40
Weighted Average Diluted Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M
Weighted Average Basic & Diluted Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M

Annual Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.82 -4.19 64 -11 -3.63 90 39 55 6.13 -5.05 145
Net Cash From Operating Activities		 -0.27 22 52 25 14 46 70 82 68 52 115
Net Cash From Continuing Operating Activities		 -0.27 22 52 25 14 46 70 82 68 52 115
Net Income / (Loss) Continuing Operations		 -1.35 10 46 60 18 122 46 46 58 50 24
Consolidated Net Income / (Loss)		 -1.35 10 46 60 18 122 46 46 58 50 24
Depreciation Expense		 0.33 18 19 19 18 18 18 18 18 28 46
Amortization Expense		 0.52 - - 0.00 0.47 1.35 1.08 0.94 1.06 1.83 4.05
Non-Cash Adjustments To Reconcile Net Income		 0.50 0.99 -6.49 -4.18 9.31 -100 31 38 27 37 43
Changes in Operating Assets and Liabilities, net		 -0.28 -7.21 -6.57 -50 -32 4.08 -25 -20 -36 -64 -2.22
Net Cash From Investing Activities		 -3.20 -8.96 27 -25 -181 95 17 -7.11 -66 -192 -539
Net Cash From Continuing Investing Activities		 -3.20 -8.96 27 -25 -181 95 17 -7.11 -66 -192 -539
Purchase of Property, Plant & Equipment		 -0.04 -3.31 -2.08 -1.17 -1.04 -1.16 -19 -23 -29 -8.03 -10
Acquisitions		 -3.36 -2.44 0.00 -17 -53 -21 -16 -16 -6.84 -152 -549
Purchase of Investments		 - -5.21 -10 -7.91 -127 -1.94 -28 -1.85 -26 -30 -1.71
Divestitures		 0.00 0.00 37 0.00 0.00 53 6.38 - 0.00 0.00 15
Other Investing Activities, net		 -0.24 0.00 0.23 - 0.00 0.00 5.93 1.96 -3.68 -2.23 6.32
Net Cash From Financing Activities		 1.66 -17 -15 -11 163 -52 -48 -20 3.42 135 569
Net Cash From Continuing Financing Activities		 1.66 -17 -15 -11 163 -52 -48 -20 3.42 135 569
Repayment of Debt		 -1.47 -2.26 -9.10 -0.59 -55 -9.61 -239 -4.43 -208 -18 -512
Repurchase of Common Equity		 - -0.52 -3.18 -5.05 -13 -0.54 -6.47 -9.25 -10 -0.94 -15
Payment of Dividends		 -0.60 -26 -10 -18 -62 -52 -33 -19 -62 -4.04 -7.89
Issuance of Debt		 3.00 0.00 5.00 8.00 290 0.00 181 3.60 285 172 1,119
Other Financing Activities, net		 -0.00 0.26 0.59 4.00 3.12 11 9.06 8.63 -1.00 -14 -14
Cash Interest Paid		 0.77 0.06 0.05 0.46 4.26 8.51 4.16 6.67 14 30 46
Cash Income Taxes Paid		 0.03 29 24 24 20 62 37 47 57 44 0.00

Quarterly Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -20 20 41 -9.49 23 -60 -30 81 124 -30 49
Net Cash From Operating Activities		 15 19 5.98 23 34 -11 17 91 9.96 -2.89 68
Net Cash From Continuing Operating Activities		 15 19 5.98 23 34 -11 17 91 9.96 -2.89 68
Net Income / (Loss) Continuing Operations		 28 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56 13
Consolidated Net Income / (Loss)		 28 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56 13
Depreciation Expense		 4.31 4.90 5.10 7.44 7.26 8.13 6.85 6.90 16 16 15
Amortization Expense		 0.24 0.35 0.46 0.46 0.46 0.45 0.69 1.05 1.15 1.16 1.13
Non-Cash Adjustments To Reconcile Net Income		 5.98 5.22 14 -30 7.62 11 1.82 68 -4.91 -30 36
Changes in Operating Assets and Liabilities, net		 -23 8.92 -30 23 -0.34 -23 1.05 5.00 -2.96 2.71 2.49
Net Cash From Investing Activities		 -35 -11 -71 -80 -8.11 -33 -2.39 -1.08 -534 -1.06 -2.84
Net Cash From Continuing Investing Activities		 -35 -11 -71 -80 -8.11 -33 -2.39 -1.08 -534 -1.06 -2.84
Purchase of Property, Plant & Equipment		 -4.11 -7.06 -0.37 -2.84 -2.30 -2.53 -3.07 -1.42 -2.55 -3.06 -4.00
Acquisitions		 -5.02 -1.84 -51 -70 -0.91 -31 0.00 - -549 -0.05 0.00
Purchase of Investments		 -25 -2.03 -20 -4.88 -5.00 -0.03 0.00 -1.03 -0.66 - 0.00
Divestitures		 - - - - - - 0.00 - - - 0.00
Other Investing Activities, net		 -0.70 -1.00 0.01 -2.31 0.10 - 0.68 1.47 2.19 2.06 1.16
Net Cash From Financing Activities		 -0.51 12 106 47 -3.19 -15 -44 -8.64 648 -26 -16
Net Cash From Continuing Financing Activities		 -0.51 12 106 47 -3.19 -15 -44 -8.64 648 -26 -16
Repayment of Debt		 -0.35 -208 -3.68 -7.56 -4.14 -3.89 -447 -7.90 -50 -8.75 -12
Repurchase of Common Equity		 -0.15 -4.43 0.00 - - -0.22 0.00 - - - -2.91
Payment of Dividends		 -1.42 -60 0.03 -1.93 -0.22 -1.94 -5.46 -0.75 -0.10 -1.56 -0.10
Issuance of Debt		 1.42 285 110 60 1.56 - 412 - 707 - 0.00
Issuance of Common Equity		 - - 0.00 - - - 0.00 -0.30 - - 0.00
Other Financing Activities, net		 - -0.73 0.00 -3.58 -0.39 -9.22 -4.05 -1.00 -8.79 -0.61 -1.17
Cash Interest Paid		 3.41 4.58 6.43 8.18 8.58 7.23 7.36 6.18 17 16 15
Cash Income Taxes Paid		 - 49 0.19 36 2.53 5.67 4.34 0.39 - -4.73 0.00

Annual Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 350 491 513 729 817 867 966 933 1,355 2,219
Total Current Assets		 9.85 81 144 173 329 339 404 428 462 638 863
Cash & Equivalents		 5.01 55 100 107 103 193 233 288 294 288 429
Note & Lease Receivable		 - - - 0.00 23 0.00 4.00 3.12 - 0.00 4.93
Accounts Receivable		 4.05 22 20 57 76 61 90 117 137 305 401
Prepaid Expenses		 0.79 1.85 5.14 7.39 10 17 19 15 17 25 26
Current Deferred & Refundable Income Taxes		 - - - - - - - 0.00 11 19 1.80
Plant, Property, & Equipment, net		 0.58 10 14 13 12 30 53 109 7.17 14 57
Total Noncurrent Assets		 4.56 258 333 327 388 449 410 430 465 702 1,298
Long-Term Investments		 - 35 22 35 29 80 43 43 32 48 26
Noncurrent Note & Lease Receivables		 - 5.20 15 18 0.00 4.63 0.57 0.00 26 51 49
Goodwill		 2.17 103 190 186 239 239 246 269 279 419 865
Intangible Assets		 1.38 108 104 87 103 87 83 77 72 118 271
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - 16 16 16 16 26
Other Noncurrent Operating Assets		 0.75 6.94 2.38 1.95 17 38 21 25 40 49 61
Total Liabilities & Shareholders' Equity		 15 350 491 513 729 817 867 966 933 1,355 2,219
Total Liabilities		 16 100 154 106 368 372 357 408 523 841 1,660
Total Current Liabilities		 5.97 51 110 72 105 115 115 149 219 366 615
Short-Term Debt		 1.04 0.10 0.61 0.04 9.50 11 0.78 0.62 20 9.38 48
Accounts Payable		 3.34 9.13 20 27 29 46 54 58 68 114 199
Current Deferred & Payable Income Tax Liabilities		 - 2.81 3.20 12 4.53 4.22 0.00 4.28 - - 0.00
Other Current Liabilities		 1.59 39 85 34 62 54 59 85 131 242 368
Total Noncurrent Liabilities		 10 49 45 34 262 257 242 259 304 475 1,045
Long-Term Debt		 7.69 - - 0.00 232 230 183 203 259 425 991
Noncurrent Deferred & Payable Income Tax Liabilities		 0.17 47 25 20 18 11 30 14 4.07 4.56 5.49
Other Noncurrent Operating Liabilities		 2.14 2.00 19 1.19 12 16 29 41 41 45 49
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 163 172 225 169 114 57 14 -206 -203 -235
Total Equity & Noncontrolling Interests		 -0.99 88 164 182 192 331 454 544 617 717 793
Total Preferred & Common Equity		 -2.82 87 160 181 192 331 448 543 614 713 779
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -2.82 87 160 181 192 331 448 543 614 713 779
Common Stock		 17 88 158 163 160 261 311 360 371 426 471
Retained Earnings		 -19 -0.77 1.73 18 32 70 137 182 243 286 308
Noncontrolling Interest		 1.83 0.38 4.24 1.00 0.79 0.09 5.94 1.75 2.43 4.01 14

Quarterly Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 999 1,027 1,073 1,226 1,252 1,285 1,331 1,442 2,237 2,359 2,282
Total Current Assets		 455 465 476 539 570 597 613 729 884 1,004 919
Cash & Equivalents		 275 294 274 335 325 348 259 340 462 478 401
Note & Lease Receivable		 0.97 0.97 0.97 - - - - - 5.91 4.66 3.32
Accounts Receivable		 153 151 184 184 203 210 313 357 391 495 489
Prepaid Expenses		 22 15 14 17 17 21 24 22 23 26 26
Current Deferred & Refundable Income Taxes		 0.00 - - 0.00 22 16 16 7.89 0.00 0.00 0.00
Plant, Property, & Equipment, net		 113 124 129 7.99 10 12 17 18 56 60 63
Total Noncurrent Assets		 431 438 468 679 672 676 701 695 1,297 1,295 1,300
Long-Term Investments		 44 49 47 42 42 44 47 47 27 27 28
Noncurrent Note & Lease Receivables		 - - 25 47 49 55 48 48 48 49 49
Goodwill		 269 274 276 410 410 410 416 417 863 875 887
Intangible Assets		 78 74 74 120 116 109 112 106 285 257 243
Noncurrent Deferred & Refundable Income Taxes		 16 16 16 16 16 16 16 16 16 26 26
Other Noncurrent Operating Assets		 24 25 30 44 39 43 62 61 57 61 67
Total Liabilities & Shareholders' Equity		 999 1,027 1,073 1,226 1,252 1,285 1,331 1,442 2,237 2,359 2,282
Total Liabilities		 434 444 458 774 774 778 814 904 1,682 1,781 1,684
Total Current Liabilities		 173 186 203 355 310 313 361 460 630 745 748
Short-Term Debt		 0.62 2.63 2.99 21 17 15 13 13 48 48 54
Accounts Payable		 58 59 59 154 103 101 110 124 214 225 250
Current Deferred & Payable Income Tax Liabilities		 11 20 30 5.52 - - - - 4.92 2.51 2.08
Other Current Liabilities		 102 104 110 174 189 196 238 323 363 470 442
Total Noncurrent Liabilities		 260 258 255 419 464 465 452 445 1,053 1,036 936
Long-Term Debt		 205 205 206 368 425 423 404 401 1,002 980 883
Noncurrent Deferred & Payable Income Tax Liabilities		 14 12 12 3.76 3.25 2.86 4.20 2.59 4.43 7.40 8.80
Other Noncurrent Operating Liabilities		 40 39 36 45 36 39 44 41 46 49 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 14 14 18 -206 -204 -203 -233 -234 -234 -238 -242
Total Equity & Noncontrolling Interests		 551 570 598 658 683 710 750 772 789 815 841
Total Preferred & Common Equity		 548 566 594 653 679 705 745 765 776 800 830
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 548 566 594 653 679 705 745 765 776 800 830
Common Stock		 353 357 363 396 402 411 452 463 473 478 488
Retained Earnings		 196 209 231 258 277 293 293 302 302 323 342
Noncontrolling Interest		 2.71 3.74 4.00 4.49 4.13 5.00 5.07 6.07 14 15 11

Annual Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.40
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -0.49 6.22 32 65 22 55 58 55 54 55 48
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 7.36% 6.09% 4.79% 2.61%
Earnings before Interest and Taxes (EBIT)		 0.14 27 36 90 35 82 84 87 86 95 76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.00 32 55 109 54 101 102 105 105 125 125
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.48 -298 155 -16 -55 64 43 -12 120 -194 -479
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.46 319 197 277 354 345 360 427 361 610 1,139
Increase / (Decrease) in Invested Capital		 4.99 634 -123 80 77 -8.68 15 67 -66 249 527
Book Value per Share		 ($0.06) $29.28 $26.51 $5.30 $5.49 $6.10 $8.07 $9.57 $10.54 $12.67 $13.84
Tangible Book Value per Share		 ($0.13) ($20.87) ($22.12) ($2.70) ($4.30) $0.09 $2.14 $3.47 $4.53 $3.12 ($6.34)
Total Capital		 7.74 501 338 407 603 686 694 763 689 949 1,597
Total Debt		 8.73 0.29 1.23 0.56 242 241 184 204 278 435 1,039
Total Long-Term Debt		 7.69 0.00 0.62 0.52 232 230 183 203 259 425 991
Net Debt		 3.72 -100 -140 -143 -7.45 -100 -145 -132 -50 96 581
Capital Expenditures (CapEx)		 0.04 6.61 2.08 1.17 1.04 1.11 19 23 29 8.03 10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.09 -28 -84 -7.14 13 -27 4.01 -13 -34 -8.57 -134
Debt-free Net Working Capital (DFNWC)		 4.92 61 35 101 233 234 291 280 262 282 296
Net Working Capital (NWC)		 3.89 61 35 101 224 224 290 280 243 273 248
Net Nonoperating Expense (NNE)		 0.86 -0.72 -13 4.23 4.50 -67 12 9.32 -3.36 5.27 24
Net Nonoperating Obligations (NNO)		 3.45 -100 -140 -130 -7.18 -100 -151 -132 -49 96 581
Total Depreciation and Amortization (D&A)		 0.86 36 19 19 19 20 19 18 19 30 50
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.33) $0.00 $0.33 $0.41 $1.04 $1.69 $0.00 $1.30 $0.91 $0.46
Adjusted Weighted Average Basic Shares Outstanding		 0.00 30.42M 0.00 32.89M 34.71M 36.53M 55.96M 0.00 55.42M 56.25M 55.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.38) $0.00 $0.29 $0.39 $1.01 $1.63 $0.00 $1.29 $0.90 $0.46
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 5.75M 0.00 37.91M 36.40M 37.45M 55.96M 0.00 55.42M 56.25M 55.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.79) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 10.43M 0.00 35.80M 52.80M 54.59M 55.96M 0.00 55.42M 56.25M 55.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.49 6.39 35 67 24 55 58 55 54 55 48
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 56,288,415.00 55,603,598.00 55,716,220.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 56,288,415.00 55,603,598.00 55,716,220.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.11 0.26 0.35
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 20.00% 19.90% 39.65% 37.49% 88.43% 53.43% 34.66% 99.71% - 55.56% 48.52%
EBITDA Growth		 -69.42% 49.74% 29.65% -16.29% 120.07% -29.24% -33.04% -6.96% - 103.79% 77.64%
EBIT Growth		 -106.87% 56.89% 24.06% -24.82% 292.38% -42.63% -40.42% -38.28% - 95.73% 71.02%
NOPAT Growth		 137.12% 47.08% 37.36% -30.03% 27.81% -37.03% -40.08% -81.87% - 42.56% 88.46%
Net Income Growth		 89.35% 35.03% 25.08% -32.15% -8,173.40% -63.11% -53.28% -94.33% - 111.08% 80.62%
EPS Growth		 471.43% 10.71% 42.86% -29.79% -153.85% -54.84% -52.50% -96.97% - 107.14% 110.53%
Operating Cash Flow Growth		 -77.28% -22.58% 0.00% 0.00% -156.73% 178.18% 292.01% -70.70% - 309.31% 0.00%
Free Cash Flow Firm Growth		 197.13% 116.51% -287.15% -215.27% -476.86% -2,126.82% 102.12% -1,719.80% - -202.55% -29,178.74%
Invested Capital Growth		 -15.36% 3.06% 23.57% 10.13% 68.92% 35.20% 1.91% 101.78% - 75.37% 96.87%
Revenue Q/Q Growth		 1.40% 0.00% 20.26% -1.55% 38.96% -6.74% 5.55% 46.00% - 1.53% 0.00%
EBITDA Q/Q Growth		 -89.97% 0.00% 33.82% -13.12% -73.63% 130.79% 27.97% 20.90% - 25.29% 0.00%
EBIT Q/Q Growth		 -101.78% 0.00% 33.78% -15.34% -95.45% 1,013.53% 38.94% -12.29% - 52.41% 0.00%
NOPAT Q/Q Growth		 -98.63% 0.00% -2.65% -2.37% -97.50% 2,545.37% -7.37% -70.46% - 18.21% 0.00%
Net Income Q/Q Growth		 -100.34% 0.00% 29.68% -13.19% -140.97% 179.99% 64.22% -89.46% - 100.11% 0.00%
EPS Q/Q Growth		 -44.68% 0.00% 29.03% -17.50% -142.42% 200.00% 35.71% -94.74% - 141.67% 0.00%
Operating Cash Flow Q/Q Growth		 25.28% 0.00% 0.00% 0.00% -132.22% 251.87% 446.70% -89.05% - 2,458.14% 0.00%
Free Cash Flow Firm Q/Q Growth		 147.86% 0.00% -1,243.46% 63.73% -710.37% 39.69% 101.20% -31,243.02% - 11.72% 0.00%
Invested Capital Q/Q Growth		 -27.90% 0.00% 18.93% 0.09% 10.59% 2.70% -10.35% 98.18% - -3.73% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 11.04% 18.29% 15.11% 15.35% 7.59% 11.50% 11.91% 10.17% - 10.96% 10.70%
EBITDA Margin		 1.28% 8.04% 8.95% 7.90% 1.50% 3.71% 4.50% 3.72% - 4.86% 5.38%
Operating Margin		 -1.10% 7.45% 6.18% 5.94% 0.11% 3.32% 3.11% 2.01% - 2.96% 3.53%
EBIT Margin		 -0.20% 6.67% 7.42% 6.38% 0.21% 2.49% 3.28% 1.97% - 3.14% 3.78%
Profit (Net Income) Margin		 -0.03% 4.17% 4.50% 3.97% -1.17% 1.00% 1.56% 0.11% - 1.36% 1.90%
Tax Burden Percent		 -10.18% 70.25% 68.55% 70.79% 410.40% 64.78% 60.72% 18.99% - 66.62% 67.81%
Interest Burden Percent		 -127.84% 89.03% 88.43% 87.80% -136.43% 62.09% 78.29% 30.09% - 65.10% 74.04%
Effective Tax Rate		 110.18% 29.75% 31.45% 29.21% 0.00% 35.22% 39.28% 81.01% - 33.38% 32.19%
Return on Invested Capital (ROIC)		 0.39% 0.00% 0.00% 0.00% 0.32% 8.87% 8.20% 1.33% - 8.05% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.93% 0.00% 0.00% 0.00% -35.02% -2.93% 3.79% 0.48% - 6.18% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -0.17% 0.00% 0.00% 0.00% -1.77% -0.36% 0.36% 0.27% - 3.56% 0.00%
Return on Equity (ROE)		 0.22% 0.00% 0.00% 0.00% -1.46% 8.51% 8.56% 1.60% - 11.61% 0.00%
Cash Return on Invested Capital (CROIC)		 30.46% 0.00% 0.00% 0.00% -39.90% -21.28% 4.88% -65.10% - -48.50% 0.00%
Operating Return on Assets (OROA)		 -0.30% 0.00% 0.00% 0.00% 0.37% 4.39% 5.89% 3.24% - 6.00% 0.00%
Return on Assets (ROA)		 -0.04% 0.00% 0.00% 0.00% -2.08% 1.76% 2.80% 0.19% - 2.60% 0.00%
Return on Common Equity (ROCE)		 0.26% 0.00% 0.00% 0.00% -2.09% 12.26% 12.16% 2.23% - 16.39% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 5.27% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.39 21 21 20 0.50 13 12 3.65 16 19 23
NOPAT Margin		 0.11% 5.24% 4.24% 4.20% 0.08% 2.15% 1.89% 0.38% - 1.97% 2.39%
Net Nonoperating Expense Percent (NNEP)		 -0.54% -8.28% 3.89% -3.28% 35.34% 11.80% 4.41% 0.85% - 1.86% 1.81%
Return On Investment Capital (ROIC_SIMPLE)		 0.04% - - - 0.04% 1.14% 1.04% 0.20% 0.88% 1.03% 1.31%
Cost of Revenue to Revenue		 88.96% 81.71% 84.89% 84.65% 92.41% 88.50% 88.09% 89.83% - 89.04% 89.30%
SG&A Expenses to Revenue		 10.75% 9.58% 7.39% 7.90% 6.26% 7.08% 7.75% 6.53% - 6.40% 5.57%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 12.14% 10.84% 8.92% 9.41% 7.48% 8.18% 8.80% 8.16% - 8.00% 7.17%
Earnings before Interest and Taxes (EBIT)		 -0.72 27 36 31 1.39 15 21 19 20 30 37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.53 33 44 38 9.97 23 29 36 37 47 52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.46 0.00 0.00 0.00 2.49 2.33 1.82 2.06 - 1.71 3.12
Price to Tangible Book Value (P/TBV)		 8.05 0.00 0.00 0.00 10.12 8.01 5.74 0.00 - 0.00 0.00
Price to Revenue (P/Rev)		 1.53 0.00 0.00 0.00 0.87 0.77 0.58 0.55 - 0.39 0.00
Price to Earnings (P/E)		 34.96 0.00 0.00 0.00 41.11 49.66 55.22 167.32 - 45.19 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 2.86% 0.00% 0.00% 0.00% 2.43% 2.01% 1.81% 0.60% - 2.21% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.17 0.00 0.00 0.00 2.74 2.58 2.12 1.74 - 1.51 2.59
Enterprise Value to Revenue (EV/Rev)		 1.35 0.00 0.00 0.00 0.82 0.72 0.49 0.67 - 0.47 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 17.81 0.00 0.00 0.00 13.40 14.06 11.83 19.73 - 11.15 0.00
Enterprise Value to EBIT (EV/EBIT)		 21.70 0.00 0.00 0.00 17.59 19.40 17.30 33.82 - 18.41 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 34.31 0.00 0.00 0.00 30.26 34.31 31.58 98.59 - 30.90 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.40 0.00 0.00 0.00 32.01 25.77 9.12 18.15 - 10.03 26.54
Enterprise Value to Free Cash Flow (EV/FCFF)		 15.57 0.00 0.00 0.00 0.00 0.00 43.86 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.68 0.86 0.92 0.86 0.85 0.80 0.77 1.89 - 1.78 1.56
Long-Term Debt to Equity		 0.63 0.82 0.89 0.83 0.83 0.78 0.75 1.81 - 1.70 1.47
Financial Leverage		 -0.19 -0.10 -0.06 -0.06 0.05 0.12 0.10 0.57 - 0.58 0.47
Leverage Ratio		 1.96 2.19 2.15 2.10 2.47 2.64 2.65 3.32 - 3.37 3.28
Compound Leverage Factor		 -2.51 1.95 1.90 1.84 -3.38 1.64 2.08 1.00 - 2.19 2.43
Debt to Total Capital		 40.40% 46.31% 48.01% 46.35% 45.81% 44.58% 43.46% 65.43% - 64.02% 61.01%
Short-Term Debt to Total Capital		 2.83% 2.46% 1.85% 1.59% 0.99% 1.34% 1.31% 2.98% - 2.98% 3.51%
Long-Term Debt to Total Capital		 37.57% 43.85% 46.16% 44.76% 44.82% 43.24% 42.15% 62.45% - 61.04% 57.50%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -29.52% -23.86% -21.74% -20.90% -20.93% -24.37% -23.91% -13.76% - -13.88% -15.09%
Common Equity to Total Capital		 89.12% 77.55% 73.73% 74.54% 75.11% 79.80% 80.45% 48.33% - 49.86% 54.08%
Debt to EBITDA		 2.65 0.00 0.00 0.00 3.49 3.61 4.11 10.71 - 6.88 0.00
Net Debt to EBITDA		 -0.48 0.00 0.00 0.00 0.77 0.94 0.24 5.70 - 3.50 0.00
Long-Term Debt to EBITDA		 2.47 0.00 0.00 0.00 3.41 3.51 3.98 10.22 - 6.56 0.00
Debt to NOPAT		 5.11 0.00 0.00 0.00 7.87 8.82 10.96 53.52 - 19.07 0.00
Net Debt to NOPAT		 -0.92 0.00 0.00 0.00 1.73 2.30 0.64 28.50 - 9.68 0.00
Long-Term Debt to NOPAT		 4.75 0.00 0.00 0.00 7.70 8.56 10.63 51.08 - 18.18 0.00
Altman Z-Score		 4.60 0.00 0.00 0.00 3.31 3.55 3.17 2.22 - 2.32 0.00
Noncontrolling Interest Sharing Ratio		 -19.34% 0.00% 0.00% 0.00% -43.46% -44.19% -42.07% -39.40% - -41.13% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.11 1.52 1.84 1.91 1.75 1.70 1.59 1.40 - 1.35 1.23
Quick Ratio		 1.98 1.47 1.71 1.79 1.63 1.59 1.52 1.37 - 1.31 1.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 66 7.40 -85 -31 -249 -150 1.79 -558 -511 -454 -521
Operating Cash Flow to CapEx		 273.49% 1,619.78% 0.00% 0.00% -432.56% 541.60% 6,401.41% 390.13% - 1,701.40% 0.00%
Free Cash Flow to Firm to Interest Expense		 12.16 0.98 -9.85 -3.46 -30.80 -20.51 0.24 -31.50 - -28.17 -32.58
Operating Cash Flow to Interest Expense		 3.56 0.79 0.00 0.00 -1.36 2.28 12.31 0.56 - 4.23 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.26 0.74 0.00 0.00 -1.67 1.86 12.12 0.42 - 3.98 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.46 0.00 0.00 0.00 1.78 1.76 1.80 1.64 - 1.91 0.00
Accounts Receivable Turnover		 10.93 0.00 0.00 0.00 9.19 9.06 8.63 9.64 - 8.73 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 23.97 0.00 0.00 0.00 189.74 181.25 172.15 84.77 - 92.32 0.00
Accounts Payable Turnover		 18.70 0.00 0.00 0.00 19.37 14.98 18.87 16.50 - 18.78 0.00
Days Sales Outstanding (DSO)		 33.39 0.00 0.00 0.00 39.70 40.31 42.29 37.87 - 41.83 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 19.52 0.00 0.00 0.00 18.84 24.37 19.35 22.12 - 19.43 0.00
Cash Conversion Cycle (CCC)		 13.87 0.00 0.00 0.00 20.86 15.94 22.95 15.75 - 22.39 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 361 464 551 552 610 627 562 1,114 1,139 1,099 1,106
Invested Capital Turnover		 3.52 0.00 0.00 0.00 4.19 4.13 4.35 3.48 - 4.09 0.00
Increase / (Decrease) in Invested Capital		 -66 14 105 51 249 163 11 562 527 473 544
Enterprise Value (EV)		 1,869 0.00 0.00 0.00 1,671 1,619 1,191 1,934 - 1,665 2,863
Market Capitalization		 2,123 0.00 0.00 0.00 1,774 1,738 1,395 1,596 - 1,366 2,587
Book Value per Share		 $10.54 $11.79 $12.12 $12.53 $12.67 $13.25 $13.65 $13.83 $13.84 $14.39 $14.90
Tangible Book Value per Share		 $4.53 $2.23 $2.73 $3.31 $3.12 $3.86 $4.33 ($6.65) ($6.34) ($5.96) ($5.39)
Total Capital		 689 843 921 945 949 934 952 1,605 1,597 1,605 1,535
Total Debt		 278 390 442 438 435 416 414 1,050 1,039 1,028 936
Total Long-Term Debt		 259 369 425 423 425 404 401 1,002 991 980 883
Net Debt		 -50 11 72 44 96 109 24 559 581 522 508
Capital Expenditures (CapEx)		 7.06 0.37 0.00 0.00 2.53 3.07 1.42 2.55 3.06 4.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -133 -50 -51 -8.57 3.59 -60 -162 -134 -172 -175
Debt-free Net Working Capital (DFNWC)		 262 204 278 299 282 265 282 302 296 307 225
Net Working Capital (NWC)		 243 184 261 284 273 252 269 254 248 259 172
Net Nonoperating Expense (NNE)		 0.49 4.31 -1.26 1.14 8.28 7.11 2.13 2.57 9.52 5.88 4.82
Net Nonoperating Obligations (NNO)		 -49 11 73 45 96 109 24 559 581 522 508
Total Depreciation and Amortization (D&A)		 5.25 5.55 7.44 7.26 8.58 7.54 7.95 17 18 17 16
Debt-free, Cash-free Net Working Capital to Revenue		 -2.45% 0.00% 0.00% 0.00% -0.42% 0.16% -2.49% -5.59% - -4.87% 0.00%
Debt-free Net Working Capital to Revenue		 18.92% 0.00% 0.00% 0.00% 13.87% 11.75% 11.65% 10.41% - 8.69% 0.00%
Net Working Capital to Revenue		 17.51% 0.00% 0.00% 0.00% 13.41% 11.20% 11.14% 8.76% - 7.34% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.27 $0.31 $0.40 $0.34 ($0.14) $0.14 $0.19 $0.01 $0.12 $0.30 $0.40
Adjusted Weighted Average Basic Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M
Adjusted Diluted Earnings per Share		 $0.26 $0.31 $0.40 $0.33 ($0.14) $0.14 $0.19 $0.01 $0.12 $0.29 $0.40
Adjusted Weighted Average Diluted Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M 55.72M 55.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.71 21 21 20 0.50 13 12 13 16 19 23
Normalized NOPAT Margin		 -0.77% 5.24% 4.24% 4.20% 0.08% 2.15% 1.89% 1.41% - 1.97% 2.39%
Pre Tax Income Margin		 0.26% 5.94% 6.56% 5.60% -0.28% 1.55% 2.57% 0.59% - 2.04% 2.80%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.13 3.55 4.20 3.45 0.17 2.12 2.91 1.06 - 1.88 2.30
NOPAT to Interest Expense		 0.07 2.79 2.40 2.27 0.06 1.82 1.67 0.21 - 1.18 1.46
EBIT Less CapEx to Interest Expense		 -1.43 3.51 0.00 0.00 -0.14 1.70 2.72 0.92 - 1.63 0.00
NOPAT Less CapEx to Interest Expense		 -1.23 2.74 0.00 0.00 -0.25 1.40 1.48 0.06 - 0.93 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 107.44% 0.00% 0.00% 0.00% 7.86% 24.02% 29.89% 83.61% - 8.18% 0.00%
Augmented Payout Ratio		 131.85% 0.00% 0.00% 0.00% 9.74% 29.76% 29.89% 83.61% - 67.35% 0.00%

Financials Breakdown Chart

Key Financial Trends

Astrana Health’s recent results show strong revenue growth and improving earnings, although margins and balance-sheet leverage remain important risks for investors. Revenue reached $972.5 million in Q2 2026, up 48.5% from $654.8 million in Q2 2025 and nearly three times the $348.2 million reported in Q2 2023. However, the company’s gross margin has steadily narrowed as revenue has expanded, falling from approximately 15.9% in Q2 2023 to 10.7% in Q2 2026.

Profitability improved substantially in the latest quarter. Operating income rose to $34.3 million from $28.5 million in Q1 2026 and $20.3 million in Q2 2025. Net income attributable to common shareholders increased to $19.7 million, or $0.40 per diluted share, compared with $14.4 million in Q1 2026 and $9.4 million in Q2 2025.

  • Rapid revenue expansion: Q2 2026 revenue increased 48.5% year over year to $972.5 million. Revenue has also grown strongly across comparable quarters, from $348.2 million in Q2 2023 to $486.3 million in Q2 2024, $654.8 million in Q2 2025 and $972.5 million in Q2 2026.
  • Improving earnings and operating income: Common-shareholder net income more than doubled year over year to $19.7 million, while operating income increased 69.0% from Q2 2025. Sequentially, common net income rose 36.7% from Q1 2026.
  • Better operating efficiency in the latest quarter: Selling, general and administrative expense declined to $54.2 million in Q2 2026 from $61.7 million in Q1 2026, even as revenue increased. This helped operating expenses fall 9.4% sequentially.
  • Positive operating cash flow: Astrana generated $68.1 million of operating cash flow in Q1 2026, a significant improvement from the $2.9 million operating cash outflow reported in Q4 2025. The company has generally produced positive operating cash flow in most recent quarters.
  • Debt reduction during Q2: Total short- and long-term debt declined to approximately $936.5 million at June 30, 2026, from $1.03 billion at March 31, 2026. The reduction suggests some progress in deleveraging following the company’s acquisition-related borrowing in 2025.
  • Liquidity remains adequate but less comfortable: Cash and equivalents were $400.8 million at the end of Q2 2026, down from $478.4 million in Q1. Current assets of $919.2 million exceeded current liabilities of $747.6 million, implying a current ratio of approximately 1.23.
  • Cash-flow data for Q2 is not provided: The latest cash-flow statement supplied is for Q1 2026, so investors should review the company’s Q2 filing for confirmation that earnings converted into cash and to assess the reasons for the $77.6 million sequential decline in cash.
  • Gross-margin pressure continues: Gross profit increased to $104.0 million, but gross margin declined to approximately 10.7% from 11.9% in Q2 2025 and 15.1% in Q2 2024. Sustained margin compression could limit the benefit of Astrana’s strong top-line growth.
  • Interest costs remain substantial: Q2 2026 interest expense was $16.0 million, consuming nearly half of operating income. Although interest expense declined modestly from Q1 2026, it remains more than twice the $7.4 million reported in Q2 2023.
  • Significant intangible-asset exposure: Goodwill and intangible assets totaled approximately $1.13 billion, or nearly half of total assets, at June 30, 2026. A deterioration in acquired businesses could lead to impairment charges and reduce reported equity.

Overall, Astrana Health is demonstrating compelling scale and earnings growth, supported by strong revenue momentum and recent operating-cost control. The main issues for shareholders are whether the company can stabilize gross margins, continue reducing debt and convert accounting earnings into consistent free cash flow.

09/11/26 11:17 PM ETAI Generated. May Contain Errors.

Astrana Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Astrana Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Astrana Health's net income appears to be on an upward trend, with a most recent value of $24.08 million in 2025, falling from -$1.35 million in 2015. The previous period was $49.93 million in 2024. View Astrana Health's forecast to see where analysts expect Astrana Health to go next.

Astrana Health's total operating income in 2025 was $78.53 million, based on the following breakdown:
  • Total Gross Profit: $341.53 million
  • Total Operating Expenses: $263.01 million

Over the last 10 years, Astrana Health's total revenue changed from $32.99 million in 2015 to $3.18 billion in 2025, a change of 9,544.7%.

Astrana Health's total liabilities were at $1.66 billion at the end of 2025, a 97.5% increase from 2024, and a 10,286.6% increase since 2015.

In the past 10 years, Astrana Health's cash and equivalents has ranged from $5.01 million in 2015 to $429.47 million in 2025, and is currently $429.47 million as of their latest financial filing in 2025.

Over the last 10 years, Astrana Health's book value per share changed from -0.06 in 2015 to 13.84 in 2025, a change of -24,011.2%.


Related Companies

Financial statements for NASDAQ:ASTH last updated on 9/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel